BH
Benchmark Holdings plc
BHCCF · OTC
$0.37 +0.00% (+$0.00)
Market Cap £166.1M
P/E Ratio 3.61x
Div. Yield -
ROE 18.62%
Bulios Fair Price
$0.27
26.2% downside
Current Price
$0.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BHCCF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
54 /100
Fair P/E 3.61x
P/S 3.27x
P/FCF 67.15x
Growth
0 /100
Declining Rev. growth 10.27%
Book val. growth 7.04%
EPS growth N/A
Profitability
50 /100
Moderate Gross margin 47.79%
Net margin 90.60%
FCF margin 4.87%
Quality
41 /100
Average ROIC 9.69%
ROE 18.62%
Asset turnover 0.12x
Debt
69 /100
Low Debt/Equity 0.27x
Current ratio 2.78x
Int. coverage -6.36x
Stability
4 /100
Unstable Beta 0.04x
Rev. volatility 37.93%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BHCCF
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Patrick Waty
Employees
800
Headquarters
Sheffield
Upcoming events
02 DEC
Earnings
Upcoming earnings report